Analysis of Novogen Ltd

Very interesting article on NVGN which highlights the current progress and  possible success of Novogen Ltd

The Recent Success Of Novogen's Experimental Cancer Drugs Is Making Headlines

March 25th 2015

http://seekingalpha.com/article/302...experimental-cancer-drugs-is-making-headlines


The company has developed several prospective therapeutic solutions based on these technologies which will be headed to trials in the next year. NVGN's pipeline includes:

• Cantrixil, a chemotherapeutic developed by a joint venture between Novogen and Yale University for the treatment of a wide range of early-stage and late-stage cancers, but currently focusing on ovarian cancer.
• TRXE-0025, the first drug of its kind specifically designed to kill the full hierarchy of cells within prostate cancer.
• Trilexium, or TRXE-009, a cytotoxic chemotherapy being developed for the treatment of brain cancers in adults and children and for malignant melanoma.
• Anisina, based on the ATM technology, is a new class of cytotoxic chemotherapy which can provide comprehensive destruction of a cancer cell's cytoskeleton in combination with microtubule-targeting drugs.

GLAH